AddedRisk Factors
There remains substantial uncertainty regarding the duration of existing and newly announced tariffs, potential changes or pauses to such tariffs, tariff levels, and whether further additional tariffs or other retaliatory actions may be imposed, modified, or suspended, and the impacts of such actions on our business. We are continuing to monitor and evaluate these “developments” and assess their potential impact on our business, financial condition, and results of operations.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedRisk Factors
Delays in the release of Chinese government stimulus spending have had a material adverse effect on our business, results of operations and financial condition, and may continue to do so for the foreseeable future.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedRisk Factors
A significant portion of our revenue is derived from sales into China, some of which are directly funded through Chinese government stimulus programs for high-end medical and industrial research instrumentation. In 2025, the release of such Chinese government stimulus spending was delayed, which has negatively affected our sales growth into China and consequently has had an adverse effect on our business, results of operations, and financial condition in 2025. Our revenue in China for the year ended December 31, 2025, was $475.8 million and remained flat compared to $471.2 million for the year ended December 31, 2024. If the release of the Chinese government’s stimulus spending continues to be delayed or recurs, our sales into China may continue to be negatively affected and our business, results of operations, and financial condition may be adversely affected in the foreseeable future. Furthermore, we are subject to significant risks associated with the trading relationship between the U.S. and China, which is currently characterized by significant uncertainty. In addition to tariffs newly imposed by the U.S. and China, which have fluctuated and remain volatile, and may increase our costs, there may be additional import, export, tax, or other regulatory changes effected by the U.S. and Chinese governments in the future that could also adversely affect our business and results of operations.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedRisk Factors
•the impact of the recent U.S. government shutdown and its potentially adverse impact on the global economy;
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RemovedRisk Factors
•Unfavorable economic or political conditions in the countries in which we operate may have an adverse impact on our business results or financial condition;
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedRisk Factors
•If we lose our strategic partners, our marketing and sales efforts could be impaired;
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedRisk Factors
Our businesses and results of operations are affected by international, national and regional economic and political conditions. Our businesses or financial results may be adversely impacted by unfavorable changes in economic or political conditions in the countries and markets in which we operate, including, among others, adverse changes in interest rates or tax rates, volatility in financial and commodity markets, contraction in the availability of credit in the marketplace, higher tariffs, including those that have been or may be imposed by the new presidential administration in the U.S., armed hostilities, such as the ongoing conflict between Russia and Ukraine or conflict in the Middle East and surrounding areas, and other events related thereto, such as economic sanctions and trade restrictions, geopolitical tensions, including tensions in China and other regions, changes in capital spending patterns, and renegotiation of existing trade agreements in the United States or countries that could adversely affect our supply chain and our business.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedRisk Factors
The new U.S. presidential administration has imposed or threatened to impose tariffs ranging from 10-25% on a variety of countries, including China, Mexico, Canada and the EU, and products, including steel, aluminum, copper, automobiles, and digital services, and is likely to continue to do so in the future. In addition, the U.S. has threatened the imposition of reciprocal tariffs on those countries who impose unequal tariffs or taxes on U.S. exports. While to date, the only tariff increase in effect is the additional 10% tariff on U.S. imports from China, which is potentially increasing to 20% on March 4, 2025, there is no guarantee that other threatened tariff increases will not become effective in the future. Given the current uncertainty around the threat of tariff increases, it is not possible to estimate the potential effect or to determine the level of materiality to the Company. Such tariff increases, if adopted and applicable to U.S. imports by the Company or its suppliers, could result in increased costs, including potential costs related to shifting more production to the U.S. or other countries, that might be material to the Company.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedRisk Factors
The United States has implemented tariffs on certain imported goods and the new presidential administration in the US has imposed or threatened to impose additional tariffs on certain imported products, including reciprocal tariffs. These additional tariffs could include items imported by us from China or other countries. In addition, China has imposed tariffs on a wide range of American products in retaliation for these new American tariffs. As a result, there is a concern that the imposition of additional tariffs by the United States could result in the adoption of additional tariffs by China and other countries as well. Any resulting trade war could negatively impact the global market for scientific instruments and could have a significant adverse effect on our business. The imposition of tariffs on items imported by us from China or other countries could increase our costs and could result in lowering our gross margin on products sold. Conversely, any imposition by China of tariffs on items that we export to China could adversely impact our customers’ ability to purchase our products and our competitive position in China or increase our costs, which could have a material adverse effect on our business and results of operations.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedRisk Factors
If we lose our strategic partners, our marketing and sales efforts could be impaired.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedRisk Factors
Decentralization necessarily places significant control and decision-making powers in the hands of local management, which presents certain risks, including the risk that we may be slower to detect or react to compliance-related matters and that “company-wide” business initiatives may be more challenging or costly to implement, and the risk of noncompliance or failures higher than they may be in a more centralized operating environment. In addition, key business group resources and our corporate functions responsible for supporting our decentralized operations, may also not be able to detect or resolve financial, operational, and compliance matters on a timely basis. Our failure to adapt our financial, operational and compliance controls and systems to effectively manage our decentralized business and comply with our obligations as a public company could materially and adversely affect our business, financial condition or results of operations.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RewordedRisk Factors
We have experienced supply chain interruptions or increased costs as a result of general global economic conditions, including economic instability, changes to governmental policies and programs, changes in tax laws and regulations, export controls, economic sanctions and trade restrictions, including those related to the ongoing conflict between Russia and Ukraine or conflict in the Middle East and surrounding areas, changes to trade policies, including higher tariff rates and customs duties imposed or that may be imposed by the new presidential administration in the U.S., continued threat of terrorism and heightened security and military action in response thereto, or any other current or future acts of terrorism, war (such as the ongoing geopolitical tensions and military conflicts in China and other regions between the U.S. and China ), a tight labor market and other factors, including natural events and disasters.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
Most of our outstanding debt is in the United States and there are We have substantial cash requirements funding obligations in the United States to service debt interest obligations, fund operations, capital expenditures expenditures, and our declared dividends on our common stock and finance potential acquisitions or share repurchases. our dividends on the Series A Mandatory Convertible Preferred Stock.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
A meaningful portion of our revenue is derived from U.S. academic institutions, research organizations and other entities that rely in part on U.S. academic and government funding, including NIH grants, NIH, NSF and any reduction in, modification of the terms and allowable overhead rates of, or delay in such research funding, could adversely affect our U.S. academic and governmental customers, and our revenues and financial performance. DOE grants.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
Economic factors that could adversely influence demand for our products include the impact of geopolitical tensions and any related sanctions implemented, continued uncertainty about global economic conditions, including as a result of any natural disasters, pandemics, or epidemics, leading to ongoing reductions in investment, changes in government spending levels and/or priorities, the size and availability of government budgets, customers’ and suppliers’ access to credit and other macroeconomic factors affecting government, academic or industrial spending behavior.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
We recorded net losses gains from currency translation adjustments of $115.1 million for the year ended December 31, 2025, and net losses of $79.6 million during the year ended December 31, 2024, and net gains of $76.2 million during the year ended December 31, 2023. 2024.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
If we experience any significant disruption of those facilities for any reason, such as war or other geopolitical conflicts, strikes or other labor unrest, power interruptions, fire, earthquakes, or other events beyond our control, we may be unable to manufacture the relevant products at previous levels or at all.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
If U.S, U.S. academic and governmental researchers experience experiencing material reductions or delays in government funding, or modifications of the terms or conditions of funding, including allowable overhead rates, they may reduce have reduced or delay delayed their purchases of our products and services, which could have a material effect on has adversely affected our revenues business and financial performance. results of operations.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
However, During the year ended December 31, 2025, the Company recorded an impairment loss losses for certain goodwill and intangible assets and certain right of use assets as disclosed in Note 12, Restructuring 6, Goodwill and asset impairments Intangible Assets to our consolidated financial statements included in Item 8 of this Annual Report on Form 10-K.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
The effects of changes in currency exchange rates increased our 2025 revenue by approximately $77.6 million, or 2.3%, decreased our 2024 revenue by approximately $13.1 million, or 0.4%, and increased our 2023 revenue by approximately $11.2 million, or 0.4%, and decreased our 2022 revenue by approximately $168.0 million, or 6.9%. 0.4%.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
These policies are based on a wide variety of factors, including the resources available to make purchases, the spending priorities among various types of equipment, policies regarding spending during recessionary periods, changes in the political climate, including disruptions or changes to funding of other government agencies, changes to governmental policies and programs, including loans, grants, guarantees and other subsidies, and changes to government spending policies, including shifts in funding priorities.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
When We are unable to predict when and how the Inclusive Framework agreement will be enacted into law in these remaining countries; however, when and how this framework is adopted or enacted by the various countries in which we do business will increase tax complexity and may increase uncertainty and adversely affect our provision for income taxes in the U.S. and non-U.S. jurisdictions.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
The following risk factors should be considered in conjunction with the other information included in this Annual Report on Form 10-K. 10-K, including “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our audited consolidated financial statements and related notes.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
If this any data is compromised, destroyed or inappropriately disclosed, it could have a material adverse effect, including damage to our reputation, and our relationships with our employees, customers, suppliers and other business partners, decrease the value of our investments in research, development and engineering, disrupt our manufacturing processes, result in significant expenses to address and resolve the issues, fines or litigation or other proceedings by affected individuals, customers, suppliers, business partners or regulatory authorities.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
We sell some certain products through third party agents, including distributors and value-added resellers.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
A substantial Furthermore, a portion of our sales of selected products consists of sales to third parties who incorporate our products into their systems.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
We may not be able to obtain sufficient quantities of required components on the same or substantially the same terms.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
The non-GAAP CER revenue decline during the year ended December 31, 2025, was driven primarily by slower demand in industrial and semiconductor markets for our analytical instruments, partially offset by higher revenue from hospital and clinical markets as well as the current year impact of recent acquisitions.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
The decrease in non-GAAP gross profit and gross profit margin during the year ended December 31, 2025, was driven by an increase in cost of goods sold due to higher U.S. tariffs, foreign exchange headwinds from a declining U.S. Dollar, and the overall revenue mix, partially offset by the impact of cost savings initiatives.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
Year Ended December 31, 2025 2024 Operating income $ 68.2 2.0 $ 253.1 7.5% Non-GAAP adjustments: Restructuring costs 77.4 2.3 24.7 0.7% Acquisition-related costs 16.3 0.5 51.9 1.5% Acquired in-process research and development expenses 13.5 0.4 — — Acquisition-related hybrid liability adjustments (50.2) (1.5 24.1 0.8% Purchased intangible amortization 121.2 3.5 99.1 2.9% Acquisition-related litigation charges 35.3 1.0 46.0 1.4% Goodwill and intangible assets impairment charges 127.2 3.7 0.4 — Other costs 24.2 0.7 18.7 0.6% Non-GAAP operating income $ 433.1 12.6 $ 518.0 15.4%
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
The decrease in our non-GAAP operating margins during the year ended December 31, 2025, was driven primarily by lower non-GAAP gross profit, the impact of foreign currency translation, and the impact of our 2024 acquisitions, partially offset by cost savings initiatives.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
Historically, we have higher levels of revenue in the fourth quarter and lower levels of revenues in the first quarter of the year, which we believe is influenced by our customers’ budgeting cycles.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
The decrease in total gross profit and gross profit margin during the year ended December 31, 2025, was driven primarily by declines in the BSI BioSpin UHF business and the Nano Surfaces and Metrology division, combined with increased restructuring costs and impairment charges as well as the impact of U.S. tariffs and foreign exchange headwinds from a declining U.S. Dollar.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
We test goodwill for impairment annually as of October 1 or more frequently if impairment indicators arise at the reporting unit level, which is the operating segment or one level below an operating segment. Due to the current macroeconomic conditions and uncertainties related to the future forecasts, the Company concluded that it was more likely than not that the fair value of one or more of the Company’s reporting units was less than their carrying amount. As a result, the Company performed a quantitative impairment test for impairment in certain reporting units as of September 30, 2025, as these reporting units had the highest uncertainty related to quantity and timing of future cash flows. As these conditions existed as of the balance sheet date, any impairment charges are recognized in the consolidated statements of operations for the period ended September 30, 2025. The results of the valuation indicated that the carrying amount of the Bruker Spatial Biology (“BSB”) reporting unit within the Company’s BSI NANO Segment and Automation (“AUT”) reporting unit within the Company’s BSI BioSpin Segment exceeded their fair value. As a result, during the year ended December 31, 2025, the Company recorded a goodwill impairment charge of $96.5 million on the consolidated statements of operations, which represented the amount by which the carrying value of the BSB reporting unit and AUT reporting unit exceeded the respective reporting unit’s fair value.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
While we will continue to monitor these circumstances, such uncertainties, including the current macroeconomic conditions and the timing and quantity of future cash flows may impact the carrying value of our reporting units. If there are any factors that drive changes to key assumptions in our valuation inputs and if the fair value of any of our reporting units declines below the carrying value in the future, additional goodwill impairment charges may be incurred and those charges may be material. Refer to Note 6, Goodwill and Intangible Assets for further information on our goodwill impairment.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
The decrease in total operating income and operating income margin was primarily due to unfavorable revenue mix which negatively impacted gross margins, increased restructuring costs and impairment charges, the impact of U.S. tariffs, and foreign exchange headwinds from a declining U.S. Dollar. In August 2025, we announced a cost savings initiative aimed at reducing annualized costs by approximately $100 million to $120 million by the end of 2026. This cost savings initiative was implemented with the intention to improve operating income and operating margins on a company-wide basis. The planned reductions affect all parts of our business including supply chain, manufacturing, commercial operations, administrative functions and research and development.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
Recently, the U.S. government has indicated its intent to modify U.S. trade policy and, in some cases, to renegotiate, or potentially terminate, certain existing bilateral or multi-lateral trade agreements. It has also imposed or increased tariffs on foreign imports into the United States from key trading partners, including Germany and Switzerland.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
The tariff increases adopted in 2025, and the uncertainty associated with them in global markets, have resulted in lower than anticipated bookings and revenues and contributed to reduced gross margins, operating margins, and profitability, and may continue to adversely affect our business, results of operations and financial condition for the foreseeable future. For example, during the year ended December 31, 2025, our results of operations were adversely impacted by an increase in cost of goods sold as a result of increased tariffs. Changes to tariffs and trade policies between the United States and foreign countries, such as what occurred during 2025, could reduce the purchasing power of our customers by increasing costs in their operations, which in turn may lead to decreased demand for our products or services. The magnitude and duration of any reduction in customer purchasing ability is difficult to reliably predict and quantify.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
Moreover, tariffs and international trade arrangements may continue to change, potentially without warning, and to an extent that is difficult to predict. On February 20, 2026, the U.S. Supreme Court issued a ruling striking down certain tariffs previously imposed under the International Emergency Economic Powers Act (“IEEPA”). The ultimate availability, timing, and amount of any potential refunds of such tariffs remain highly uncertain and are subject to further legal, regulatory, and administrative developments. Following the Supreme Court’s decision, the U.S. presidential administration announced its intention to invoke other laws to collect tariffs and announced new tariffs on imports from all countries, in addition to any existing non-IEEPA tariffs.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RemovedMD&A
•potential energy shortages in Europe where the Company has significant operations and overall higher energy and transportation costs;
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedMD&A
During the fiscal year ended December 31, 2024, Bruker made several acquisitions including ELITechGroup, NanoString and Chemspeed. These acquisitions enable Bruker to extend our capabilities in molecular diagnostics (ELITechGroup), life science analytical instruments (NanoString) and to provide new capabilities in lab automation (Chemspeed). Refer to Note 4, Acquisitions in the consolidated financial statements.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedMD&A
The amounts listed below are in millions of dollars. Where relevant, we have also included the associated percentage margins.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedMD&A
The decrease in non-GAAP CER revenue growth was driven primarily by lower growth in our academic, government, and industrial markets against difficult high growth comparables in 2023. China was also a significant contributor to our slower growth in 2024 compared to the prior year. These markets were offset by revenue from acquisitions and organic growth.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedMD&A
The decrease in non-GAAP gross margin was primarily due to the mix impact of our 2024 acquisitions combined with a modest headwind from foreign currency.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedMD&A
The decrease in our non-GAAP operating margins in 2024 was primarily due to lower margin mix and increased costs related to 2024 acquisitions.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedMD&A
The increase in gross profit was a result of pricing and volume leverage, marginally offset by net unfavorable impact of foreign exchange rate movements compared to 2023. The decrease in gross profit margin was primarily due to mix impact of our 2024 acquisitions combined, and unfavorable foreign exchange rate movements.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedMD&A
The decrease in operating income and operating income margin was primarily due to unfavorable margin mix and increased costs related to 2024 acquisitions, and unfavorable foreign exchange rate movements.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedMD&A
In 2023, the Company recorded a gain of $144.1 million, in connection with the PhenomeX acquisition, which closed on October 2, 2023. This bargain purchase gain reflected the excess of identifiable net assets acquired, including deferred tax assets related to acquired tax NOLs, over the purchase consideration paid.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedMD&A
In 2024, following the finalization of a review of income tax positions related to change in ownership limitations assessments on NOL/R&D credits at the end of the business combination measurement period in connection with the PhenomeX acquisition, the Company recorded a charge of $8.0 million
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedMD&A
The decrease in net income and earnings per diluted share was primarily driven by lower gross and operating margins, higher tax rate, as well as the bargain purchase gain recognized in 2023 in connection with the PhenomeX acquisition.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedMD&A
Effective in the quarter ended June 30, 2024, the Company entered into a multi-currency notional cash pooling agreement with a financial institution to manage cash flow more efficiently and optimize liquidity. Refer to Note 2, Summary of Significant Accounting policies for more information on our notional cash pooling agreement.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RewordedMD&A
Selling, general and administrative 946.5 893.8 729.4 164.4 22.5 52.7 5.9 Research and development 395.2 376.5 294.8 81.7 27.7 18.7 5.0 Goodwill impairment charge 96.5 — 96.5 100.0 Other charges, net 71.3 126.1 52.2 73.9 141.6 (54.8) (43.5 Total operating expenses 1,509.5 1,396.4 1,076.4 320.0 29.7 113.1 8.1 Operating income 68.2 253.1 436.9 (183.8) (42.1 (184.9) (73.1 Bargain purchase gain and associated measurement period adjustments — (8.0) 144.1 (152.1) (105.6 8.0 100.0 Interest and other income (expense), expense, net (46.2) (38.2) (36.8) (1.4) 3.8 (8.0) 20.9 Income before income taxes, equity in income (losses) losses of unconsolidated 22.0 206.9 544.2 (337.3) (62.0 unconsolidated (184.9) (89.4 investees, net of tax, and noncontrolling interests in consolidated subsidiaries Income tax provision 29.3 91.4 117.7 (26.3) (22.3 (62.1) (67.9 Equity in income (losses) losses of unconsolidated investees, net of tax (1.0) (1.7) 2.0 (3.7) (185.0 0.7 (41.2 Consolidated net (loss) income (8.3) 113.8 428.5 (314.7) (73.4 (122.1) (107.3 Net income attributable to noncontrolling interests in 0.3 0.7 1.3 (0.6) (46.2 (0.4) (57.1 consolidated subsidiaries Net (loss) income attributable to Bruker Corporation (8.6) 113.1 (121.7) (107.6 Dividends on Series A Mandatory Convertible Preferred Stock 13.9 — 13.9 100.0 Net (loss) income attributable to Bruker Corporation common shareholders $(22.5) $113.1 $427.2 $(314.1) (73.5 (135.6) (119.9
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
We After consideration of the debt repayments made with the proceeds from the Series A Mandatory Convertible Preferred Stock described above, along with $141.5 million paydown of the 2024 term loan due in 2027 during the fourth quarter of 2025, we have a total outstanding debt of $2.1 $1.9 billion as of December 31, 2024, 2025, and a revolving credit facility that provides for up to $900.0 million of additional backup liquidity to finance working capital needs, refinance or reduce existing indebtedness, and for general corporate use use, of which $872.2 $899.3 million is undrawn. available.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Non-GAAP Constant-exchange rate (CER) (“CER”) currency revenue 3,379.5 2,953.3 $3,358.9 $3,379.5 Non-GAAP Constant-exchange rate (CER) (“CER”) currency revenue year-on-year (decrease) growth rate (0.2 14.0% 16.7% Non-GAAP Organic Revenue $3,242.6 $3,082.8 Non-GAAP Organic Revenue year-on-year (decrease) growth rate compared to prior year revenue (3.7 4.0% Non-GAAP Gross Profit 1,736.9 1,547.6 $1,712.0 $1,736.9 Non-GAAP Gross Profit Margin 49.8 51.6% 52.2% Non-GAAP Operating Income 518.0 546.3 $433.1 $518.0 Non-GAAP Operating Income Margin 12.6 15.4% 18.4% Non-GAAP Free Cash Flow 136.0 243.2 $43.3 $136.0
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Net cash provided by used in financing activities during the year ended December 31, 2024, was primarily from proceeds from long-term debt of $973.7 million (refer to Note 21, Debt), million, proceeds from our public offering of common stock of $403.0 million (refer to Note 27, Shareholders’ Equity), million, and net proceeds from our revolving line of credit of $37.6 million, primarily offset by the repayment of our 2012 Note purchase agreement of $100.0 million (refer and the payment of dividends to Note 21, Debt). common shareholders of $30.2 million.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Year Ended December 31, 2025 2024 2023 Dollar Percentage Change Change Product revenue $2,766.4 $2,759.2 $2,457.6 $301.6 12.3 $7.2 0.3 Service and other revenue 670.1 607.2 506.9 100.3 19.8 62.9 10.4 Total revenue 3,436.5 3,366.4 2,964.5 401.9 13.6 70.1 2.1 Cost of product revenue 1,486.5 1,364.5 1,165.2 199.3 17.1 122.0 8.9 Cost of service and other revenue 372.3 352.4 286.0 66.4 23.2 19.9 5.6 Total cost of revenue 1,858.8 1,716.9 1,451.2 265.7 18.3 141.9 8.3 Gross profit 1,577.7 1,649.5 1,513.3 136.2 9.0 (71.8) (4.4 Operating expenses:
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Although our consolidated financial statements have been prepared in accordance with GAAP, we believe that describing revenue excluding the effects of foreign currency, and expenses excluding costs related to restructuring actions, acquisition impairment costs, acquisitions, integration and related integration IT transformation expenses, amortization of acquired intangible assets, costs associated with our global information technology transition initiatives, and other costs (“non-GAAP adjustments”), provides meaningful supplemental information regarding our performance. performance but should not be considered in isolation from or as a replacement for the most directly comparable GAAP financial measures.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Year ended Ended December 31, 2025 2024 2023 GAAP revenue $ 3,366.4 $ 2,964.5 3,436.5 $3,366.4 Effect of changes in foreign currency translation rates (77.6) 13.1 (11.2) Non-GAAP CER currency revenue $ 3,379.5 3,358.9 $3,379.5 Acquisitions 116.3 296.7 Non-GAAP Organic revenue $ 2,953.3 GAAP Revenue growth rate 13.6% 17.1% Non-GAAP CER currency revenue growth rate 14.0% 16.7% 3,242.6 $3,082.8
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Historically, we have financed our growth and used the liquidity needs through generated from cash flow generation from operations and a combination of operations, debt financings financings, and issuances of common stock. and preferred stock to finance our growth and operating needs.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Revenue $ 3,366.4 $ 2,964.5 $3,436.5 $3,366.4 Revenue year-on-year Growth Rate 2.1 13.6% 17.1% Gross Profit 1,649.5 1,513.3 $1,577.7 $1,649.5 Gross Profit Margin 45.9 49.0% 51.0% Operating Income 253.1 436.9 $68.2 $253.1 Operating Income Margin 2.0 7.5% 14.7% Net cash provided by operating activities 251.3 350.1 $134.1 $251.3 Non-GAAP Financial Measures (see 'Non-GAAP Measures' “Non-GAAP Measures” below):
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
The decrease in consolidated net income adjusted for non-cash items was primarily due to driven by lower income as a result of unfavorable margin revenue mix combined with negative impact of new U.S. trade tariffs and increased costs related to 2024 acquisitions. foreign exchange headwinds from a declining U.S.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
For the year ended December 31, 2024, 2025, our free cash flow was $107.2 decreased by $92.7 million lower than compared to the same period in 2023, 2024, primarily due to lower net income and significant acquisition-related expenses. an increase in tax payments in 2025.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Bruker is organized into four reportable segments: the Bruker Scientific Instruments (BSI) BSI BioSpin Segment, the BSI CALID Segment, the BSI NANO Segment Segment, and the Bruker Energy & Supercon Technologies (BEST) BEST Segment.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesMD&A
Net cash provided by operating activities during the year ended December 31, 2024, resulted primarily from consolidated net income adjusted for non-cash items of $329.5 million, partially offset by a change in operating assets and liabilities, net of acquisitions of $78.2 million.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new